The Rise of ICER - The Payer Perspective
|ICER（臨床和經濟審查研究所）的興起：付款人的觀點 The Rise of ICER - The Payer Perspective|
|出版日期: 2020年07月20日||內容資訊: 英文||
How is the Institute for Clinical and Economic Review (ICER) influencing payer behavior? ICER's evidence and price benchmarking data are valued by payers but, for now, are not central to their decision making. For some, ICER's methodology is seen as a blunt instrument which fails to take into account the real-world commercial complexities of drug pricing and reimbursement. Nevertheless, payers are not slow to bring into play ICER's assessments if it suits their purpose. So how can pharma respond when ICER's assessments are referenced by payers?
ICER is becoming a force in pharma/payer relations and manufacturers need clear policies and procedures for responding to their influence. To help shape your strategy we interviewed experienced US payers with direct ICER experience. In The Rise of ICER - The Payer Perspective they outline the key issues and attitudes that shape payer thinking and thereby reveal the proactive steps pharma can undertake to mitigate risk from a negative ICER assessment, or make the most of a positive one.
"We hear more about ICER's reports from the manufacturers than we do from anybody else. I've had manufacturers come to me and say 'Hey, ICER just put out a report for this drug, but we did our own cost-effectiveness, our own version of ICER's evaluation, and we come up with a much different number.' Well, of course they did. ICER's reports seem to be more for manufacturers, because what I think they are trying to do is to come up with their own evaluation to dispute the numbers that ICER is putting out. I've had that happen a couple of times. Where they would say, 'Oh well, ICER looked at this but they should have looked at that. We looked at this, but they didn't." Pharmacy Director.
"From what I understand with value-based contracts, they often sound better than they are in reality; they're often very hard to operationalize. It's possible that ICER could help that if they were able to include very objective endpoints that would be noncontroversial for either party, and agreed upon as acceptable endpoints for that drug to reasonably meet in order to be performing the way it should. So then it might make it easier to operationalize because one of the reasons that I think we see fewer value-based contracts is oftentimes it's very hard to come up with endpoints that both parties accept as a fair result as a consequence of the particular drug, and not other confounding factors that could improve that outcome." Medical Director, Health insurer.
"We put together everything that is available: all the clinical information, all the economic information, we put that together in-house for the P&T materials. We don't base our economic discussions based on the quality-adjusted life year. We just don't look at the economics that way; we look at what's the weighted average cost, the cost per month, the cost per year." Pharmacy Director.
A detailed report exploring payer attitudes to ICER, the value they perceive in their work and how it is influencing their relationship with manufacturers:
Experts contributing to this report have been screened to ensure they:
Experts provided their own individual views, which do not necessarily reflect the views of the organizations they work for.
FirstWord's ExpertViews reports reveal the real world insights of knowledgeable experts to analyze in detail key commercial and market trends that pharma management need to understand if they are to effectively respond to critical developments. These highly-focussed reports: